Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons.

Joussain C, Le Coz O, Pichugin A, Marconi P, Lim F, Sicurella M, Salonia A, Montorsi F, Wandosell F, Foster K, Giuliano F, Epstein AL, Aranda Muñoz A.

Toxins (Basel). 2019 Feb 19;11(2). pii: E123. doi: 10.3390/toxins11020123.

2.

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients.

Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, Snyder D, Foster K.

Toxins (Basel). 2019 Feb 13;11(2). pii: E115. doi: 10.3390/toxins11020115.

3.

AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients.

Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, Foster K.

Toxins (Basel). 2018 Dec 13;10(12). pii: E535. doi: 10.3390/toxins10120535. Erratum in: Toxins (Basel). 2019 Feb 13;11(2):.

4.

The Expanding Therapeutic Utility of Botulinum Neurotoxins.

Fonfria E, Maignel J, Lezmi S, Martin V, Splevins A, Shubber S, Kalinichev M, Foster K, Picaut P, Krupp J.

Toxins (Basel). 2018 May 18;10(5). pii: E208. doi: 10.3390/toxins10050208. Review.

5.

Climate change accelerates growth of urban trees in metropolises worldwide.

Pretzsch H, Biber P, Uhl E, Dahlhausen J, Schütze G, Perkins D, Rötzer T, Caldentey J, Koike T, Con TV, Chavanne A, Toit BD, Foster K, Lefer B.

Sci Rep. 2017 Nov 13;7(1):15403. doi: 10.1038/s41598-017-14831-w.

7.

Enhanced exercise and regenerative capacity in a mouse model that violates size constraints of oxidative muscle fibres.

Omairi S, Matsakas A, Degens H, Kretz O, Hansson KA, Solbrå AV, Bruusgaard JC, Joch B, Sartori R, Giallourou N, Mitchell R, Collins-Hooper H, Foster K, Pasternack A, Ritvos O, Sandri M, Narkar V, Swann JR, Huber TB, Patel K.

Elife. 2016 Aug 5;5. pii: e16940. doi: 10.7554/eLife.16940.

8.

Serum Quetiapine Concentration Changes with Concomitant Oxcarbazepine Therapy in a Boy with Autism Spectrum Disorder.

McGrane IR, Loveland JG, Zaluski HJ, Foster KD.

J Child Adolesc Psychopharmacol. 2015 Nov;25(9):729-30. doi: 10.1089/cap.2015.0117. Epub 2015 Oct 15. No abstract available.

PMID:
26469302
9.

Propeptide-mediated inhibition of myostatin increases muscle mass through inhibiting proteolytic pathways in aged mice.

Collins-Hooper H, Sartori R, Macharia R, Visanuvimol K, Foster K, Matsakas A, Flasskamp H, Ray S, Dash PR, Sandri M, Patel K.

J Gerontol A Biol Sci Med Sci. 2014 Sep;69(9):1049-59. doi: 10.1093/gerona/glt170. Epub 2014 Jan 11.

PMID:
24414825
10.

Engineered botulinum neurotoxins as new therapeutics.

Masuyer G, Chaddock JA, Foster KA, Acharya KR.

Annu Rev Pharmacol Toxicol. 2014;54:27-51. doi: 10.1146/annurev-pharmtox-011613-135935. Epub 2013 Aug 30. Review.

PMID:
24016211
11.

Rate of return to acute care hospital based on day and time of rehabilitation admission.

Faulk CE, Cooper NR, Staneata JA, Bunch MP, Galang E, Fang X, Foster KJ.

PM R. 2013 Sep;5(9):757-62. doi: 10.1016/j.pmrj.2013.06.002. Epub 2013 Jun 14.

PMID:
23770350
12.

Highly potent delivery method of gp160 envelope vaccine combining lentivirus-like particles and DNA electrotransfer.

Vandermeulen G, Athanasopoulos T, Trundley A, Foster K, Préat V, Yáñez-Muñoz RJ, Dickson G.

J Control Release. 2012 May 10;159(3):376-83. doi: 10.1016/j.jconrel.2012.01.035. Epub 2012 Jan 28.

PMID:
22310089
13.

Engineering botulinum neurotoxin domains for activation by toxin light chain.

Stancombe PR, Masuyer G, Birch-Machin I, Beard M, Foster KA, Chaddock JA, Acharya KR.

FEBS J. 2012 Feb;279(3):515-23. doi: 10.1111/j.1742-4658.2011.08444.x. Epub 2011 Dec 23.

14.

Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons.

Yiangou Y, Anand U, Otto WR, Sinisi M, Fox M, Birch R, Foster KA, Mukerji G, Akbar A, Agarwal SK, Anand P.

J Pain Res. 2011;4:347-55. doi: 10.2147/JPR.S25189. Epub 2011 Oct 18.

15.

Targeted secretion inhibitors-innovative protein therapeutics.

Keith F, John C.

Toxins (Basel). 2010 Dec;2(12):2795-815. doi: 10.3390/toxins2122795. Epub 2010 Dec 3. Review.

16.

Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.

Koo T, Malerba A, Athanasopoulos T, Trollet C, Boldrin L, Ferry A, Popplewell L, Foster H, Foster K, Dickson G.

Hum Gene Ther. 2011 Nov;22(11):1379-88. doi: 10.1089/hum.2011.020. Epub 2011 May 25.

17.

Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.

Athanasopoulos T, Foster H, Foster K, Dickson G.

Methods Mol Biol. 2011;709:21-37. doi: 10.1007/978-1-61737-982-6_2.

PMID:
21194019
18.

Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice.

Malerba A, Sharp PS, Graham IR, Arechavala-Gomeza V, Foster K, Muntoni F, Wells DJ, Dickson G.

Mol Ther. 2011 Feb;19(2):345-54. doi: 10.1038/mt.2010.261. Epub 2010 Nov 23.

19.

Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.

Kang JK, Malerba A, Popplewell L, Foster K, Dickson G.

Mol Ther. 2011 Jan;19(1):159-64. doi: 10.1038/mt.2010.212. Epub 2010 Oct 5.

20.

Current and emerging strategies for treating hepatic encephalopathy.

Foster KJ, Lin S, Turck CJ.

Crit Care Nurs Clin North Am. 2010 Sep;22(3):341-50. doi: 10.1016/j.ccell.2010.04.007. Review.

PMID:
20691385

Supplemental Content

Loading ...
Support Center